Novo Nordisk Third Quarter 2022 Earnings: Revenues Beat Expectations

Novo Nordisk (CPH:NOVO B) Third Quarter 2022 Results

Key Financial Results

• Revenue: kr.45.6b (up 28% from 3Q 2021).
• Net income: kr.14.4b (up 19% from 3Q 2021).
• Profit margin: 32% (down from 34% in 3Q 2021). The decrease in margin was driven by higher expenses.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Novo Nordisk Revenues Beat Expectations

Revenue exceeded analyst estimates by 2.4%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Pharmaceuticals industry in Europe.

Performance of the market in Denmark.

The company's shares are up 7.4% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of Novo Nordisk's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.